ReviewCellular and molecular neurobiology2007
The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.
Review in Cellular and molecular neurobiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 60 citations in OpenAlex.
- Diurnal cortisol amplitude and fronto-limbic activity in response to stressful stimuli.Psychoneuroendocrinology · 2009Trial
- Altered Steroidome in Women with Multiple Sclerosis.International journal of molecular sciences · 2024Article
- Steroidomics in Men with Schizophrenia.International journal of molecular sciences · 2024Article
- Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia.Frontiers in psychiatry · 2023Article
- Disability progression in multiple sclerosis is associated with plasma neuroactive steroid profile.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- Network Pharmacology-Based Strategy for Elucidating the Molecular Basis Forthe Pharmacologic Effects of Licorice (Frontiers in pharmacology · 2021Article
- Novel Treatment Targets Based on Insights in the Etiology of Depression: Role of IL-6 Trans-Signaling and Stress-Induced Elevation of Glutamate and ATP.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naïve patients with schizophrenia.Psychoneuroendocrinology · 2018Article
- Neurosteroids in Schizophrenia: Pathogenic and Therapeutic Implications.Frontiers in psychiatry · 2018Review
- Therapeutic efficacy of atypical antipsychotic drugs by targeting multiple stress-related metabolic pathways.Translational psychiatry · 2017Article
- Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date.CNS drugs · 2016Review
- The impact of environmental factors in severe psychiatric disorders.Frontiers in neuroscience · 2014Review
- Pregnanolone Glutamate, a Novel Use-Dependent NMDA Receptor Inhibitor, Exerts Antidepressant-Like Properties in Animal Models.Frontiers in behavioral neuroscience · 2014Article
- Early detection of simian immunodeficiency virus in the central nervous system following oral administration to rhesus macaques.Frontiers in immunology · 2013Article
- Childhood stressful events, HPA axis and anxiety disorders.World journal of psychiatry · 2012Review
- The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia.Schizophrenia research and treatment · 2012Article
- Regulation of neurosteroid biosynthesis by neurotransmitters and neuropeptides.Frontiers in endocrinology · 2012Article
- A genomewide linkage scan of cocaine dependence and major depressive episode in two populations.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Article
- Impaired neurosteroid synthesis in multiple sclerosis.Brain : a journal of neurology · 2011Article
- Pregnanolone sulfate promotes desensitization of activated NMDA receptors.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. Neuroactive steroids are steroid hormones that exert rapid, nongenomic effects at ligand-gated ion channels. There is increasing awareness of the possible role of these steroids in the pathology and manifestation of symptoms of psychiatric disorders. The aim of this paper is to review the current knowledge of neuroactive steroid functioning in the central nervous system, and to assess the role of neuroactive steroids in the pathophysiology and treatment of symptoms of schizophrenia, depression, and anxiety disorders. Particular emphasis will be placed on GABAA receptor modulation, given the extensive knowledge of the interactions between this receptor complex, neuroactive steroids, and psychiatric illness. 2. A brief description of neuroactive steroid metabolism is followed by a discussion of the interactions of neuroactive steroids with acute and chronic stress and the HPA axis. Preclinical and clinical studies related to psychiatric disorders that have been conducted on neuroactive steroids are also described. 3. Plasma concentrations of some neuroactive steroids are altered in individuals suffering from schizophrenia, depression, or anxiety disorders compared to values in healthy controls. Some drugs used to treat these disorders have been reported to alter plasma and brain concentrations in clinical and preclinical studies, respectively. 4. Further research is warranted into the role of neuroactive steroids in the pathophysiology of psychiatric illnesses and the possible role of these steroids in the successful treatment of these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.